Immutep, a biopharmaceutical company specializing in immuno-oncology, and Eddingpharm, a specialty pharmaceutical company, have entered into an agreement for development, commercialization and manufacturing of Immutep’s ImmuFact IMP321. Financial details were not disclosed.

Eddingpharm has exclusive rights to develop and market IMP321 in mainland China, Hong Kong, Macau and Taiwan. Immutep will provide full technical support for development. Immutep and Eddingpharm plan to develop the product for first-line metastatic breast cancer as well as other first-line metastatic indications.

John Hawken, CEO, said. “Immutep is continuing the development of IMP321 in Europe and the U.S. We are in partnering discussions at present.”